The US FDA has approved Libtayofor the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. CSCC is the second most common form of skin cancer and is responsible for an estimated 7,000 deaths each year in the US, and currently accounts for approximately 20 % of all skin cancers in the US.  The number of newly diagnosed cases is expected to rise annually.   The FDA granted t...